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_____________________________________________________________________________________ 
X-ray crystallography studies as well as live-cell fluorescent imaging have recently challenged the 
traditional view of Protein-kinase CK2. Unbalanced expression of catalytic and regulatory CK2 
subunits has been observed in a variety of tissues and tumors. Thus, the potential intersubunit 
flexibility suggested by these studies raises the likely prospect that the CK2 holoenzyme complex is 
subject to disassembly and re-assembly. In this study, we show evidence for the reversible 
multimeric organization of the CK2 holoenzyme complex in vitro. We used a combination of site-
directed mutagenesis, binding experiments and functional assays to show that both in vitro and in
vivo, only a small set of primary hydrophobic residues of CK2E which contacts at the center of the 
CK2D/CK2Einterface dominates affinity. The results indicate that a double mutation in CK2E ҏ of 
amino acids - Y188 and F190 – which are complementary and fill up a hydrophobic pocket of 
CK2Dis the most disruptive to CK2D binding both in vitro and in living cells. Further 
characterization of hot spots in a cluster of hydrophobic amino acids centered around Y188-F190 
led us to the structure-based design of small peptide inhibitors. One conformationally constrained 
11-mer peptide (Pc) represents a unique CK2E-based small molecule that was particularly efficient 
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1) to antagonize the interaction between the CK2 subunits, 2) to inhibit the assembly of the CK2 
holoenzyme complex, 3) to strongly affect its substrate preference.  
Key words: CK2 protein-kinase, protein-protein interaction, cyclic peptide, peptide disruptor, hot 
spot, substrate specificity.  
_____________________________________________________________________________________ 
Abbreviations used: MBP, maltose binding protein; GST, glutathione-S-tranferase; BiFC, bimolecular 
fluorescence complementation; YFP, yellow fluorescent protein; GFP, green fluorescent protein; FRET, 
fluorescence resonance energy transfer. 
INTRODUCTION
All but a handful of the protein kinase family members are monomeric enzymes which are often regulated 
by reversible phosphorylation. In contrast, the regulation and the molecular architecture of multi-subunit 
Ser/Thr protein kinases such as phosphorylase kinase  [1], cAMP-dependent protein kinase [2], cyclin-
dependent protein kinases [3], DNA-dependent protein kinase [4], 5'-AMP-activated protein kinase [5] 
and Ikappa B kinase [6] rely on the reversible binding of regulatory subunits to the catalytic subunits of 
these enzymes. The presence of the regulatory subunit can either play a negative role on the catalytic 
subunit (ex. cAMP-dependent protein kinase [7]) or is a prerequisite for activation (ex. cyclin-dependent 
protein kinases [3]).  
Protein kinase CK2 shares with few other protein kinases a quaternary structure consisting of two catalytic 
subunits (CK2D/CK2D’) and two regulatory subunits (CK2E) [8]. However, as compared to other multi-
subunit protein kinases, CK2 exhibits notable distinguishing structural and functional features [9, 10]. 
CK2 catalytic subunits possess constitutive activity [11, 12], but CK2E is a central component of the 
tetrameric CK2 complex [13], controlling CK2 substrate specificity, cellular localization and enzymatic 
activity. In this respect, CK2E operates as a targeting subunit and/or a docking platform affecting the 
accessibility to the catalytic site of binding substrates whose phosphorylation is either stimulated or 
prevented by the CK2Esubunit [14, 15]. In this context, the spontaneous high affinity association of 
recombinant CK2 subunits in a stable heterotetrameric complex (dissociation constant KD = 5.4 nM) as 
well as numerous complementary biochemical observations led to the long-held tenet that CK2 is a strong 
obligate complex. However, this traditional view was challenged when X-ray crystallography studies 
revealed that the CK2D/CK2Einterface is smaller than the surface contacts that are usually observed in 
stable protein complexes [13]. The possible intersubunit flexibility suggested by these studies was further 
reinforced by the observation of independent movement of CK2D and CK2E in living cells [16]. In 
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addition, the presence in mouse brain and testicles of a CK2E fraction devoid of CK2D [17] and a pool of 
free CK2D' in prostate tumor cells [18] have been reported. Collectively, these observations raise the 
likely prospect that the CK2 holoenzyme complex is subject to disassembly and re-assembly [19]. As CK2 
substrates localize to many different subcellular compartments, a dynamic interaction of CK2 subunits 
should increase the kinase specificity and the assembly of the complex is a likely point of regulation [20]. 
The ability to interfere with specific protein-protein interactions has already provided powerful means of 
influencing the functions of selected proteins within the cell [21, 22]. Thus, the potential intersubunit 
flexibility of the CK2 holoenzyme complex makes it amenable to drug-discovery efforts aimed at 
inhibiting this protein-protein interaction. 
In this work, we show evidence for the reversible multimeric organization of the CK2 holoenzyme 
complex in vitro. Site-directed mutagenesis, binding experiments and functional assays provided further 
insights into the molecular interaction between the CK2 subunits demonstrating that both in vitro and in
vivo, only a small set of primary hydrophobic residues of CK2E which contacts at the center of the 
interface dominates affinity. Characterization of hot spots led us to a structure-based design of small 
peptide inhibitors derived from the CK2E carboxyterminal domain. One conformationally constrained 11-
mer peptide can efficiently antagonize the interaction between the CK2 subunits representing the first 
small molecule that binds to this hydrophobic interface. This study represents the first step of a systematic 
approach to set the framework for the discovery and development of chemical inhibitors of this 
interaction.
EXPERIMENTAL 
Materials
[J32P]-ATP (3,000 Ci/mmol) was purchased from MP Biosciences. The peptide substrate 
(RRREDEESDDEE) for CK2 kinase assay was obtained from NeoMPS. The purity of this peptide (89 %) 
was determined by HPLC on a nucleosil C18 column using a linear triethanolamine phosphate-acetonitrile 
gradient. Solvents were of analytical grade. Cyclic peptides, biotinylated cyclic peptides and Ala-mutated 
cyclic peptides were synthesized by Eurogentec. The pEYFPc1 vector was purchased from Clontech 
Laboratories. EcoRI and BamHI restriction enzymes were from Invitrogen, and SacI and AgeI from New 
England Biolabs. 
Chemicals, peptide synthesis and purification 
All chemical reagents and solvents were purchased from Sigma Aldrich, Acros or Carlo-Erba and were 
used without further purification. All protected amino acids were obtained from Advanced ChemTech 
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Europe, Bachem Biochimie SARL and France Biochem S.A.. RP-HPLC analyses were performed on 
Waters equipment. The analytical (Nucleosil 120 Å 3 Pm C18 particles, 30 x 4.6 mm2) was operated at 1.3 
mL/min and the preparative (Delta-Pak 300 Å 15 Pm C18 particles, 200 x 25 mm2) at 22 mL/min with UV 
monitoring at 214 nm and 250 nm using a linear A-B gradient (buffer A: 0.09% CF3CO2H in water; buffer 
B: 0.09% CF3CO2H in 90% acetonitrile). Mass spectra were obtained by electron spray ionization (ES-
MS) on a VG Platform II in the positive mode. 
The protected linear peptides were assembled manually on solid-phase using the standard Fmoc/t-Bu 
strategy with PyBOP® as coupling reagent on the acido labile SASRIN® resin. They were cyclizised 
directly without further purification as reported previously [23]. For all peptides, Glycine was chosen as 
the C-terminal end to secure the subsequent cyclization step from epimerization. The protected cyclic 
peptides were finally treated with a solution of TFA/TIS/H2O (95:2.5:2.5) for two hours. After 
evaporation, the cyclic peptides were purified by RP-HPLC. The purified cyclic peptides were 
homogenous and showed expected primary ion molecular weights by mass spectrometry.  
Proteins
Human recombinant His-tagged CK2D, GST-CK2D and GFP-CK2D were obtained as previously 
described [16, 24]. Expression and purification of chicken recombinant MBP-CK2E was performed as 
previously described [25]. GST-CK2E (182-215) referred as GST-E C-ter was obtained by cloning by 
PCR the 33 C-terminal amino acids of CK2Ein pGEX4T1. Two recombinant proteins, MBP-CDC25B 
(kindly provided by Bernard Ducommun, Toulouse, France) and GST-Olig2 (1-177) (personal 
communication, Thierry Buchou), were used as CK2E-dependent CK2 substrates.
In vitro kinase assay 
CK2 kinase assays were performed in a final assay volume of 18 PL containing 3 PL of CK2D (36 ng) and 
a mixture containing 1 mM of the peptide substrate, 10 mM MgCl2, and 1 PCi [J32P]-ATP. Final 
concentration of ATP was 100 PM. Assays were performed under linear kinetic conditions for 5 min at 
RT before termination by the addition of 60 PL of 4% TCA [26]. 
In vitro CK2D-CK2E interaction assay 
The CK2D-CK2Einteraction assay involved competition between plate-bound MBP-CK2Eand various 
soluble peptides for binding to soluble [35S]-methionine-labelled CK2DThe assay was performed in 
Reacti-Bind streptavidin coated high binding capacity 96-well plates (Pierce) in which each well was 
coated with 250 ng of biotinylated MBP-CK2E (Sulfo-NHS-LC-LC-Biotin with a spacer arm of 30.5 Å 
4
St
ag
2(a
) P
OS
T-P
RIN
T
Biochemical Journal Immediate Publication. Published on 23 Aug 2007 as manuscript BJ20070825
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
70
82
5
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2007 The Authors Journal compilation © 2007 Biochemical Society
length, Pierce) in 50 mM Tris-HCl, pH 7.2, 0.4 M NaCl buffer for 1 h at RT. After 3 washes with 50 mM 
Tris-HCl, pH 7.2, 0.15 M NaCl, 0.05% Tween 20, the wells were blocked with 50 mM Tris-HCl, pH 7.2, 
0.15M NaCl and 3% BSA for 1 h at RT. After 3 washes, competing peptides were added to each well in 
50 mM Tris-HCl, pH 7.2, 0.4 M NaCl, along with [35S]-methionine-labelled CK2D (105 cpm) synthetized 
in vitro by using the TnT Quick Coupled Transcription/translation System (Promega)The plates were 
incubated for 1 h at RT and after 3 washes, the radioactivity or the fluorescence of each well in the plate 
was determined using a scintillation counter. Positive control (100% competition) was determined with a 
10-fold molar excess of untagged CK2D, and negative control (0% competition) was performed in the 
absence of competitor. IC50 is defined as the concentration of peptide necessary to inhibit 50% of CK2D-
CK2E complex formation.  
Pull-down assays 
GST-tagged proteins were immobilized on glutathione-sepharose 4 Fast Flow beads (Amersham 
Biosciences), for 1 h at 4°C, in 10 mM Tris-HCl, pH 7.5. Beads were then incubated with CK2D for 1 h at 
4°C. After 4 washes, CK2D activity was measured as described above.  
MBP-CK2E (5 Pg) was immobilized on amylose beads (New England Biolabs) for 1 h at 4°C in 10 mM 
NaHPO4, pH 7.2, 0.5 M NaCl, 10 mM EMercaptoethanol, 1 mM EGTA, 0.05% Tween 20. Buffer was 
replaced by 10 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05% Tween 20. Then, increasing amounts of GST-
E C-terҏҏ were added along with 5 Pg of GST-CK2D for 20 min at 4°C. After 4 washes, 1/10 of beads were 
used for CK2 activity assay, and the remaining beads were used for CK2D detection by Western-blotting.  
Size exclusion chromatography
An Ultrogel ACA34 gel filtration column (0.5 x 30 cm) was equilibrated in 50 mM Tris-HCl, pH 7.5, 
0.4M NaCl and calibrated using aldolase (MW = 158 kDa), bovine serum albumin (MW = 68 kDa) and 
carbonic anhydrase (MW = 29 kDa) as standards. CK2D (50 Pg) alone or CK2D (50 Pg) incubated with 
GST-E C-ter (30 Pg) for 30 min at 4°C were loaded onto the column. Eluted fractions (0.25 ml) were 
collected and assayed for the presence of CK2D and GST-EC-ter by Western-blotting .  
Site-directed mutagenesis 
Site-directed mutagenesis of CK2E was performed with the pMALc2-CK2E vector using the Quick 
Change Site-Directed Mutagenesis kit (Stratagene) and specific primers from Eurogentec to generate 
different mutant MBP-CK2E proteins. Primers were for M166A sens 5’ G TTC CCC CAT GCG CTC 
TTC ATG GTG 3’, Y188A sens 5’ GTG CCC AGG CTG GCT GGG TTC AAG ATC CAC CCT ATG G 
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3’, F190A sens 5’ GTG CCC AGG CTG TAT GGG GCC AAG ATC CAC CCT ATG G 3’. MBP-CK2E
mutant ҏproteinsҏ were expressed in BL21 E. coli and purified as described previously [25] and stored at -
80°C in 10 mM Na2HPO4, pH 7.0, 0.5 M NaCl, 10 mM E-mercaptoethanol, 1 mM EGTA, and proteases 
inhibitors (Sigma). 
Surface Plasmon Resonance spectroscopy 
Surface plasmon resonance measurements were performed using a BIAcore 3000 instrument (BIAcore 
AB). The running buffer was HBS (10 mM Hepes pH 7.3, 0.15 M NaCl, 3 mM EDTA, 0.005% 
polysorbate 20). The carboxymethylated dextran surface of a CM5 sensor chip (BIAcore AB) was 
activated by injecting a solution of N-hydroxysuccinimide and N-ethyl-N-(dimethylaminopropyl) 
carbodiimide hydrochloride (coupling solution BIAcore AB). Anti-GST antibody was diluted to 30 Pg/ml 
in 10 mM acetate buffer pH 5.0 and injected over the surface of the sensor chip for 7 min at a flow rate of 
5 PL/min. The unreacted sites of the sensor chip surface were then quenched by injection of 1 M 
ethanolamine pH 8.5. GST-CK2D (50 Pg/ml) was immobilized on the surface at a flow rate of 5 PL/min 
in HBS. Different MBP-CK2E mutants were diluted to 50 Pg/ml in HBS buffer and injected over the 
surface at a flow rate of 5 PL/min. Regeneration of the surfaces was achieved by injection of 10 mM 
glycine-HCl pH 2.2.  
Plasmid constructs, cell transfections and BiFC analysis 
Full-length chicken CK2D sequence was cloned into the pEYFPc1 vector using EcoRI restriction sites,
then oriented with BamHI digestion to generate the pEYFPc1-CK2Dconstruct. Full-length mouse CK2E
sequence was cloned into the same pEYFPc1 vector using BamHI restriction sites, then oriented with 
EcoRI digestion to generate the pEYFPc1-CK2Econstruct. Subsequently, the EYFP sequence was 
substituted by the 1-154 or the 155-238 fragments of EYFP. These fragments were PCR amplified and 
inserted using SacI-AgeI to generate BiFC plasmid constructs. The resulting N- and C-terminal YFP-CK2 
fusions are referred to as: YN-CK2D, YN-CK2E, YC-CK2D, YC-CK2E respectively. Primers 
(Eurogentec) were for YN-CK2D or YN-CK2E: 5’ G CTA CCG GTC GCC ACC ATG GTG AGC AAG 
3’ and 5’CAC AAC GTC TAT ATC ATG CGA GCT CAG GCT TCG AAT TCT GC 3’ respectively. 
Primers were for YC-CK2D or YC-CK2E: 5’ CCG TCA GAT CCG CTC GCG CTA CCG GTC ATG 
GCC GAC AAG CAG AAG AAC GGC 3’ and 5’ CG AAG CTT GAG CTC GAG ATC TGA GTC CGG 
3’ respectively. All the constructs were verified by sequencing. 
HeLa cells were grown in DMEM supplemented with 10% FCS. One day before transfection, cells were 
seeded in Lab-Tek chambers (Nunc) and transfected with the different BiFC plasmid constructs using 
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Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. Four hours after 
transfection, cells were washed with PBS and incubated with fresh medium for 24 h at 37°C and then 
switched to 30°C for 2 h to promote fluorophore maturation [27]. Preliminary experiments have shown 
that a fraction of YN-CK2D or YC-CK2D and YN-CK2E or YC-CK2E could interact with endogenous 
CK2E and CK2D, trapping a part of YFP devoted to fluorescence complementation [28]. Therefore, to 
enhance the signal, immunostaining of YFP was performed by indirect immunofluorescence using the 
mouse anti-GFP antibody (Abcam) which recognizes only full-length YFP, but neither N-ter (1-154) nor 
C-ter (155-238) YFP (see Figure 1 in supplemental data). Under similar transfection conditions, 
polyclonal anti-GFP antibody (Abcam) did not discriminate between full-length and YFP-half molecules 
(data not shown). Thus, cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.5% 
Triton X-100 for 10 min, preincubated with 5% goat serum for 30 min at RT, and incubated with the 
mouse anti-GFP as primary antibody for 1 h at RT, washed with PBS and incubated with goat anti-mouse 
IgG-conjugated Cy3 (Molecular Probes) for 45 min at RT in the dark. Nuclei were stained by 2Pg/ml 
Hoechst 33342 (Sigma) and coverslips were mounted with Dako (Dakocytomation), and examined using a 
Zeiss Axiovert 200 Microscope and a 40x1.3 Plan Neofluorar objective. The results were expressed as % 
of cells that were above the fluorescence threshold observed in cells expressing only YN-CK2D or YN-
CK2EBecause the amount of expressed proteins is critical to the interpretation of results, the expression 
levels of the different chimeras were also analyzed in transfected cells by Western blotting using anti-
CK2D or CK2Eantibodies as previously described [16, 29].  
RESULTS
Reversibility of the CK2 subunit multimeric organization in vitro
Surface plasmon resonance measurements with purified recombinant CK2D and CK2E subunits showed 
that they assemble rapidly (t1/2= 60 sec) into a stable heterotetrameric complex with nanomolar affinity 
(Kd = 5.4 nM) with a ka and kd of 6.6 x 10
4 M-1 s-1 and 3.6 x 10-4 s-1 respectively [30]. However, X-ray 
crystallography has revealed that the CK2D/CK2E interface was relatively small (832 Å2) and flexible 
raising the possibility that CK2 tetramers may be subjected to disassembly and re-assembly [13]. To test 
this hypothesis we performed a competition binding assay in which complexes between MBP-CK2E and 
[35S]-methionine-labelled CK2D were incubated with increasing molar excess of CK2D. As shown in 
figure 1A, [35S]-methionine-labelled CK2D was efficiently displaced from the preformed complex by the 
CK2Dsubunit. The residual radioactivity (15%) may represent [35S]-methionine-labelled CK2D present in 
misfolded CK2 complexes that are resistant to dissociation. In the presence of a 10-fold molar excess of 
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CK2D, the t1/2 of CK2 complex dissociation was evaluated to be § 38 min showing that unlike the fast 
association of CK2 subunits (t1/2= 1 min), the kinetic of disassembly was rather slow (figure 1B). These 
data are consistent with the association/dissociation rate constants determined previously [30]. 
Molecular and functional analysis of the CK2E C-terminus 
Analysis of the crystal data has revealed the major contribution of the D/E tail contact for the stability of 
the CK2 holoenzyme [13]. In addition, CK2E mutants in which the zinc finger motif has been disrupted 
failed to dimerize and to recruit CK2D, showing that this dimerization is essential for the proper docking 
of CK2D [31, 32]. A CK2D-interacting domain was delineated by residues 181-203 in the CK2E C-
terminus [33]. Thus, we have expressed and purified from bacteria a CK2Efragmentencompassing 
residues 182-215 fused to GST (GST-E C-ter). Size exclusion chromatography analysis indicated that this 
fusion protein behaves as a dimeric protein through GST-GST interaction (data not shown). 
Reconstitution experiments showed that this mini protein was sufficient for a productive high-affinity 
interaction with CK2Din a pull-down assay (Figure 2A). Size-exclusion chromatography analysis showed 
that the free CK2D eluted as a monomer (42 kDa). In contrast, CK2D incubated with GST-E C-ter was 
eluted as free CK2D as well as a CK2D/GST-E C-ter complex with an apparent MW of 150 kDa (Figure 
2B). These data indicate that this interaction generates a stable hetero-complex bridging two catalytic 
subunits. Thus, the region delineated by residues 182-215 in GST-E C-ter contains an autonomous CK2D-
interacting domain. We then examined the effect of this CK2E domain on the formation of the CK2 
holoenzyme complex in a solid phase competition assay. As illustrated in Figure 2C, the interaction 
between CK2D and CK2Ewasstrongly impaired by the presence of increasing concentrations of the GST-
E C-ter protein. These results show that the 33 amino acids C-terminal region of CK2Ebinds tightly 
toCK2D and behaves as an antagonist of the CK2 subunit interaction.  
Identification and validation of CK2Eҏ hot spots for high-affinity CK2D binding 
The crystal structure of the CK2 holoenzyme has suggested the predominant contribution of specific 
residues for the interfacial contacts of the CK2E tail with CK2D, which were localized in a cluster of 
hydrophobic amino acids centered around Y188. As already pointed out by Niefind et al [14] this highly 
conserved segment of CK2Eforms a structural element containing a E-hairpin loop with Y188 at its top 
(Figure 3A). This analysis provided a general outline of the CK2D binding site but did not identify 
experimentally the specific residues involved in the binding. Guided by the high-resolution structure of the 
CK2 holoenzyme, we used alanine mutagenesis to target CK2Eҏ residues (M166, Y188, F190) in this 
CK2D-docking site that make the most significant contacts with CK2D. Residues within CK2D that are 
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involved in interactions with these CK2E residues are mainly hydrophobic residues like I69, P104, Y39, 
L41, V42, I57, I59, V105. In addition, carbonyl oxygen of Y188 and K191 CK2E backbone are making 
H-bonds with NH of Q36 and L41 of CK2D respectively. However it is known that the holoenzyme 
structure is stable under high ionic strength, suggesting that these H-bonds may be barely involved in the 
subunit interaction [10]. Therefore, we tested M166A, Y188A, F190A mutants by quantitative binding 
analysis. Figure 4 A shows that the CK2D binding activity of the single mutant F190A (CK2E-F) was 
significantly reduced and this activity was completely abrogated for the Y188A/ F190A double mutant 
(CK2E-YF) and for the M166A/Y188A/F190A triple mutant (CK2E-MYF). To validate these data, the 
binding properties of the CK2Emutants were also analyzed by surface plasmon resonance spectroscopy. 
As shown in Figure 4B, the binding activity of the CK2E-F single mutant was markedly decreased and the 
CK2E-YF double or the CK2E-MYF triple mutations virtually abolished interaction.  
Functional properties of CK2E mutants 
Since it is clear that in many cases, CK2Emediates the interaction between the catalytic subunits and its 
cellular substrates, thereby modulating their phosphorylation, we assumed that any mutation perturbing 
the CK2 subunit interaction would affect the phosphorylation of CK2E-dependent substrates. A functional 
analysis of WT CK2E and CK2E-M, CK2E-YF and CK2E-MYF mutants was performed testing their 
effect on the CK2-mediated phosphorylation of CDC25B [34]. The data show that, while the 
phosphorylation of CDC25B was weakly affected in the presence of the single CK2E-M mutant, the 
double CK2E-YF and triple CK2E-MYF mutants were inefficient for CK2-mediated phosphorylation of 
CDC25B (Figure 5, lanes 1-5). Similarly, autophosphorylation of the CK2E-YF and CK2E-MYF mutants 
was strongly affected (Figure 5, lanes 6-9) indicating that these mutants are also defective for the 
supramolecular organization of the CK2 holoenzyme [35]. Thus, Y188 and F190 represent key CK2Ehot 
spot residues for a functional interaction with CK2D in vitro. 
In vivo validation of CK2E hot spots 
To visualize the CK2 subunit interaction in living cells, we applied a BiFC assay (Bimolecular 
Fluorescence Complementation) which allows the investigation of interacting molecules in vivo [27]. The 
BiFC assay is based on the formation of a fluorescent complex by fragments of the Yellow Fluorescent 
Protein (YFP) brought together by the association of two interaction partners fused to non-fluorescent 
YFP half-molecules. This approach enables visualization of the proteins interaction under conditions that 
closely reflect the normal physiological environment. Previous work from our laboratory have shown that 
visualization of CK2 subunit interaction by fluorescence resonance energy transfer (FRET) analysis 
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required that the fluorochromes should be positioned on the N-terminal region of CK2D and CK2E [36]. 
Thus, the (1-154; YN) and (155-238; YC) fragments of YFP were fused to the NH2 terminus of CK2D,
CK2Eor different CK2E mutants. The corresponding constructs were co-transfected in HeLa cells and the 
BiFC assay was performed using immunostaining of YFP to enhance the signal as described in 
Experimental Procedures (see also Figure 1 in supplementary data). Cells transfected with full length YFP 
fused to CK2D (Figure 6A, panel a) or to CK2E (not shown) exhibit a strong fluorescence after YFP 
immunostaining. As expected, cells separately transfected with YN-CK2D, YC-CK2E expression vectors 
(Figure 6A, panels b and c) or YN-CK2E, YC-CK2D(not shown) did not exhibit any detectable 
fluorescence even after immunostaining. Co-transfection of YN-CK2D and YC-CK2E yielded 
reconstitution of YFP upon specific binding in 36.8% of the cells (Figure 6A panel d and Figure 6B). 
When the fusion partners YN-CK2Dand YC-CK2E were cross-exchanged, reconstitution was also 
observed (not shown). Similarly, co-expression of YN-CK2D and YC fused to CK2E-M, CK2E-Yor
CK2E-Fsingle mutants allowed the observation of a characteristic fluorescent signal (Figure 6A panel e 
and Figure 6B). In contrast, a weak complementation (14.4% of the cells above the fluorescence 
threshold) was observed with CK2E-YF double mutant and YFP reconstitution was barely detected (2.4%) 
for YN fused to CK2E-MYF triple mutant (Figure 6A, panel f), despite strong protein expression as 
determined on immunoblots (Figure 6C, lanes 3, 6). These results indicate that substitutions of CK2E
residues Y188 and F190 strongly influence the efficiency of bimolecular complex formation supporting 
the hypothesis that their mutation inhibit interaction with CK2D in the cellular context. 
Constrained cyclic peptides as antagonists of CK2 subunit interaction 
The dramatic effects of the two hot spot mutants on CK2Ebinding observed both in vitro and in the 
cellular context suggest that the interaction domain could be narrowed down to a short contiguous 
sequence. High-resolution structure of the CK2 holoenzyme has revealed that a cluster of well-defined 
hydrophobic residues present on the CK2E chain are facing hydrophobic residues N-terminally located at 
the outer surface formed by the juxtaposition of the anti-parallel E4/E5 sheets of CK2D [13, 37]. This 
cluster which contains the identified hot spots Y188 and F190 represents a segment of highly conserved 
residues (186RLYGFKIH193) exhibiting a specific structural feature: it points away from the protein core, 
forms a 90° E-hairpin loop with Y188 at its top which binds into a shallow hydrophobic groove present in 
the E4/E5 sheets of CK2D [13]. The interface relies on the steric complementarity between this CK2D
groove and the hydrophobic face of the CK2Eҏ hairloop and, in particular, on a triad of CK2Eҏ amino acids 
Y188, G189, F190 which inserts deep into the CK2D groove (Figure 3A). To assess whether peptides 
derived from this CK2E region could antagonize the CK2 subunit interaction, we developed a binding 
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assay in which MBP-CK2E was bound on streptavidin-coated microtiter plates and incubated with [35S]-
methionine-labeled CK2D. Compounds that disrupt the CK2D/CK2E complex thus register reduced 
radioactivity relative to the background. We then used the X-ray structure of CK2E in the holoenzyme 
complex as a template for the design of conformationally constrained peptides derived from the CK2E
carboxyterminal domain and centered around the Y188 and F190 hot spots. A eight residue peptide (186R-
H193) which contained the cluster of hydrophobic residues (L187, Y188, I192) and three additional glycine 
residues was cyclized via two cysteins  to staple its conformation and to mimic the binding face of CK2E
with CK2D (figure 3B). The biological activity of this peptide referred as Pc peptide, was first examined 
in a CK2D pull-down assay. Figure 7A shows that the same amount of CK2D activity could be found 
associated to biotinylated CK2E or biotinylated Pc indicating that this cyclic peptide stably interacts with 
CK2D. This interaction could be also visualized by surface plasmon resonance spectroscopy (data not 
shown). To assess whether the Pc peptide could antagonize the CK2 subunit interaction, a CK2 subunit 
binding assay was performed in the presence of increasing concentrations of Pc peptide. Representative 
results are shown in Figure 7B. The presence of the Pc peptide strongly antagonized the formation of the 
CK2 complex (IC50= 3 PM). Importantly, an almost complete disassembly of the preformed complex was 
observed in the presence of the Pc peptide (IC50= 6.5 PM). The effect of varying the length from 8 to 14 
amino acids in a series of head-to-tail cyclized peptide analogues was examined. Although all length 
variants significantly blocked the interaction, the eleven residue Pc peptide was the most effective (Figure 
7C). Noteworthy, a linear form of Pc was much less active in this binding assay (IC50= 30 PM) and a 
linear form of Pc with an inverted sequence was without effect, showing that both the sequence and the 
constrained conformation of the peptide are essential for its antagonist activity. To explore the functional 
impact of each amino acid side chain on the Pc peptide antagonist activity, we synthesized a series of 
cyclic peptides in which each amino acid in the sequence RLYGFKIH was subjected to a systematic 
single-site replacement strategy. These derivatives were first tested at two fixed peptide concentrations 
(1.5 and 15 PM) in the CK2 subunit interaction assay. As shown in Figure 8A, the largest effects of single 
alanine mutants were observed for residues F7 or G6 and to a less extent for residues Y5 and I9. Alanine 
substitutions of neighboring positions (R3, L4, K8, H10) caused marginal reductions in binding indicating 
that these residues serve a more passive role. Quantitative determination of the IC50 values further shows 
that the most disruptive alanine substitutions are confined in a small patch that extends from Y5 to F7 and 
the largest reduction in binding was for F7 (Figure 8B). In accord with the definition of the corresponding 
CK2Ehot spots, these data highlight the importance of these residues for the biological activity of peptide 
Pc. A functional analysis of this peptide was performed testing its effect on the phosphorylation of the 
Olig-2 transcription factor which is catalyzed exclusively by the tetrameric form of CK2 (personal 
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communication, Thierry Buchou). Figure 9 shows that the presence of increasing concentrations of Pc led 
to a strong decrease of the original Olig-2 phosphorylation, reflecting a Pc-induced progressive 
dissociation of the catalytically active CK2 holoenzyme complex. 
DISCUSSION 
The irreversible nature of the CK2 holoenzyme formation has been challenged by both its crystal structure 
and live cell imaging studies [13, 16]. Free populations of each CK2 subunit have been identified in 
several organs [17] and differential subcellular localizations have also been reported for CK2D and 
CK2EIn many cases, CK2Eoperates as a docking platform affecting the accessibility of the catalytic site 
for binding substrates [15]. From a structural point of view, the CK2E subunit can provide CK2 specificity 
by either shielding a substantial surface of the CK2D subunit or at the same time, providing a new surface 
near the catalytic active site. Since the free catalytic subunit and the holoenzyme exhibit divergent 
substrate preferences, it could be predicted that such a balance is crucial in the control of the many cellular 
processes that are governed by this multi-faceted enzyme [19].  
Here we show that the CK2 holoenzyme complex is subject to disassembly and re-assembly in vitro. The 
rather slow rate of dissociation of the holoenzyme complex in vitro might not reflect the situation in intact 
cells where interacting partners could induce conformational changes, shifting the balance in favor of the 
dissociation [19]. A relatively small portion of CK2Eencompassing the 33-residue C-terminal region 
constitutes a minimum CK2Dbinding domain which is necessary and sufficient for high affinity 
interaction with CK2D. The CK2 holoenzyme crystal structure has revealed that several residues in this 
domain make significant contacts with CK2D. Based on these data, the finding that emerges from our 
mutagenesis study is that only a small set of primary hydrophobic contacts at the center of the interface 
dominates affinity in vitro allowing the identification of residues Y188 and F190 as the most important 
interaction points of CK2EMutations of these residues had strong functional consequences since the 
CK2E-YF and CK2E-MYF mutants were 1) unable to sustain the formation of a stable CK2 complex, 2) 
defective for its supramolecular organization and 3) inefficient for CK2-mediated phosphorylation of a 
CK2E-dependent substrate like CDC25B. 
BiFC analysis from YN-CK2D and YC-CK2E reproducibly demonstrated a specific interaction whereas 
the individual tagged proteins did not yield fluorescence. A characteristic BiFC pattern was detected with 
CK2E-M, CK2E-Yor CK2E-F single mutants indicating that these CK2Emutants mediate  
CK2Drecognition. In contrast, BiFC fluorescence could be monitored only at a very low intensity with 
CK2E-YF double mutant demonstrating that these two amino acids are essential for a productive complex 
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formation in the normal cellular environment. These observations which corroborated our in vitro
quantitative binding analysis were supportive of the ability to design peptides that can affect the CK2 
subunit interaction. This led us to a structure-based design of CK2E-derived conformationally constrained 
peptides that can efficiently antagonize this high affinity interaction. Among a series of cyclic peptides, 
the disulfide bridged Pc peptide was the most active peptide variant. This cyclic peptide was considerably 
more potent than its identical linear form, indicating that cyclization staples the peptide in a fixed 
conformation, a strategy that is known to strongly enhance peptide affinity for their target by limiting 
flexibility and multiple conformational changes [38]. Consistent with the identification of Y188 and F190 
as CK2Ehot spots, alanine-scanning analysis has confirmed that change of these two hydrophobic 
residues was highly detrimental for the inhibitory activity of the Pc peptide.  
Potential biological relevance of CK2 subunit antagonists
To our knowledge, the 11-mer peptide Pc represents the first small antagonist that binds to the CK2 
interface and inhibits its high affinity subunit interaction. Functional analysis showed that Pc could act as 
an antagonist of CK2E-dependent phosphorylation through the inhibition/disruption of the CK2 
holoenzyme complex. Structural modifications of this cyclic peptide such as attachment to cell permeable 
adducts will be required to confer in vivo activity. Future efforts should also focus on the design of 
peptidomimetics with enhanced activity and selectivity. 
Alternatively, our study further indicates that it should be possible to obtain small chemical molecules that 
bind to the CK2Dhydrophobic groove and inhibit its interaction with CK2E in a manner similar to the Pc 
peptide. Molecules that selectively inhibit the CK2 subunit interaction would be useful in determining the 
importance of CK2E in the control of the many cellular processes that are governed by this 
multifunctional kinase. In particular, such inhibitors would provide more rapid and reversible tools than 
siRNA or overexpression methods for correctly identifying relevant CK2E-dependent substrates. They 
will also serve as leads for the rational design of function-specific drugs that disrupt some actions of CK2, 
but leave other intact, allowing to deregulate specific intracellular pathways. Furthermore, selective 
disruption of the CK2D/CK2E interaction could find important applications to pharmacologically test the 
importance of this interaction in tumor cell growth. With the help of structure-based rational design, the 
idea of finding small chemical molecules with significantly higher affinities for CK2D using the Pc 
peptide as a lead molecule does not seem far-fetched. 
FOOTNOTES 
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FIGURE LEGENDS 
Figure 1 Reversibility of the CK2 subunit assembly in vitro
(A) Exchange of CK2D in the subunit complex. Preformed complexes between immobilized MBP-CK2E
and [35S]-methionine-labelled-CK2D were incubated for 1h with increasing concentrations of unlabelled 
CK2D. After washing, the amount of [35S]-methionine-labelled-CK2Dpresent in the complex was 
determined by radioactivity counting. (B) Kinetic of dissociation of the CK2 subunit complex. Preformed 
complexes between [35S]-methionine-labelled-CK2D and MBP-CK2E were incubated for different time 
with a 10-fold molar excess of unlabelled CK2D. After washing, the amount of [35S]-methionine-labelled-
CK2D remaining in the complex was determined by radioactivity counting. Results are the means r S.D. 
(n = 3). 
Figure 2 Interaction of a CK2E C-terminal fragment with CK2D
(A) Stable association of CK2D with a GST-E C-ter fragment. Agarose beads containing different GST-
tagged proteins were incubated with or without CK2D as indicated. After washing, the amount of 
associated CK2D was evaluated by CK2 kinase assay as described in the experimental section. (B) Size 
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exclusion chromatography of either free CK2D (upper panel) or CK2D/GST-E C-ter complex (lower 
panel). Collected fractions were assayed for the presence of CK2D by Western blotting. Elution of 
molecular weight standards is indicated. (C) Antagonist effect of the GST-EC-ter fragment. Immobilized 
MBP-CK2E was incubated with the indicated fold excess of GST-EC-ter and a fixed amount of CK2D.
After washing, the amount of associated CK2D was assessed by CK2 kinase assay and Western blotting. 
Figure 3 Structure and mode of binding of Pc peptide on CK2D
(A) Surface representation of the binding pocket of CK2D interacting with a short C-terminal loop of 
CK2E. Crystal structure of the CK2 holoenzyme shows that a C-terminal fragment of the CK2Echain 
encompassing residues 186-193 (colored in green) forms a loop inserting into a deep hydrophobic pocket 
of CK2D [14]. Surface representation of the CK2D cleft in grey highlights its pocket-like characteristics. 
The phenyl and phenol rings of the two non-polar and aromatic CK2E residues Y188 and F190 
respectively (colored in red), are in quasi planar opposite orientation and fit tightly in it. M166 (colored in 
red) located on the second CK2E chain (colored in yellow) is labeled. (B) Molecular model of Pc peptide 
in CK2D pocket. A rough molecular model of Pc peptide (in blue) was obtained from the CK2E1structure
previously determined (PDB code 1JWH, [13]). In details, the CK2E1 structure segment 
(186RLYGFKIH193 in green) was taken as template for the corresponding central peptide segment and the 
terminal aminoacids were manually added using the program Coot [39]. A basic geometric idealization of 
peptide bonds was then performed using the program Refmac 5 [40] from Ccp4 [41]. For clarity, only key 
interacting residues of CK2E1 are shown (in red). The cystein disulfide bridge is colored in orange. The
superimposition of Pc peptide with the CK2E-C-terminal loop demonstrates that Pc emulates the 
interaction of the natural ligand CK2EwithCK2DPictures were prepared with the Chimera software [42] 
and the 1JWH PDB structure [14]. 
Figure 4 CK2D binding activity of CK2E mutant proteins 
(A) Solid phase CK2D binding assay of different CK2E mutants. Immobilized WT CK2E was incubated 
with [35S]-methionine-labelled CK2D in the presence of increasing concentrations of soluble WT MBP-
CK2E or MBP-CK2Emutants as indicated. After washing, the amount of associated CK2D was evaluated 
by radioactivity counting. Results are the means r S.D. (n = 3). (B) Real time binding kinetics between 
immobilized GST-CK2D and different MBP-CK2E mutant proteins measured by surface plasmon 
resonance. The interaction between immobilized GST-CK2D and MBP-CK2E mutants was recorded as 
described in Experimental Procedures.  
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Figure 5 Phosphorylation of CDC25B by CK2Din presence of CK2E or CK2E mutants 
MBP-CDC25B (1.5 PM) was pre-incubated for 15 min with CK2D (0.6 PM) in the presence of  0.35 PM
of WT MBP-CK2E or the indicated MBP-CK2Emutants. Phosphorylation reaction was carried out for 5 
min at RT in the presence of 25 PM [J32P]-ATP-MgCl2. Phosphorylated proteins were separated on SDS 
PAGE and analyzed by autoradiography (upper panel) or Coomassie staining (lower panel). 1: CDC25B, 
2: WT MBP-CK2E + CDC25B, 3: MBP-CK2E-M + CDC25B, 4: MBP-CK2E-YF + CDC25B, 5: MBP-
CK2E-MYF + CDC25B, 6: WT MBP-CK2E, 7: MBP-CK2E-M, 8: MBP-CK2E-YF, 9: MBP-CK2E-
MYF.
Figure 6 Visualization of interactions between CK2D and CK2E or CK2Emutants in living cells by 
Bimolecular Fluorescence Complementation 
(A) Immunofluorescence images of HeLa cells transfected with plasmids expressing the YFP fragments 
fused to CK2D, CK2E or CK2Emutants as indicated in each panel. Twenty four hours after transfection, 
immunostaining of YFP was performed to enhance the signal as described in Experimental Procedures. 
The diagrams on the left of the images represent the experimental strategies used. (B) Quantification of 
the BiFC signal in cells co-transfected with different plasmid constructs. Results are expressed as % of
cells that were above the fluorescence threshold observed in cells expressing only YN-CK2Dor YN-
CK2EC) Western blot analysis of the levels of protein expression. Cells corresponding to panels d, e, f 
in Figure 6A that expressed the indicated proteins were harvested, and the cell extracts were analysed by 
Western blotting using anti-CK2D(lanes 1, 2, 3) and CK2E(lanes 4, 5, 6) antibodies. Lanes 1, 4: YN-
CK2D + WT YC-CK2E, lanes 2, 5: YN-CK2D + YC-CK2E-M, lanes 3, 6: YN-CK2D + YC-CK2E-MYF.
Figure 7 Disruption of CK2 subunits interaction by CK2E-derived cyclic peptides 
(A) Binding of Pc peptide or CK2Eto CK2DIncreasing concentrations of biotinylated Pc peptide (-Ÿ-)
or biotinylated MBP-CK2E (-'-) were immobilized on streptavidin beads and incubated with CK2D (0.3 
PM) for 15 min at 4°C. After washing, the amount of associated CK2D was evaluated by CK2 kinase 
assay. (B) Inhibition of CK2D/CK2E complex ҏformation by Pc peptide (-Ÿ-). Immobilized MBP-CK2E
was incubated with increasing concentrations of Pc peptide, followed by the addition of [35S]-methionine-
labelled CK2D (105 cpm). After washing, bound CK2D was determined by radioactivity counting. 
Dissociation of preformed CK2D/CK2E complex by Pc peptide (-Ŷ-). [35S]-methionine-labelled CK2D
was incubated with immobilized MBP-CK2E, followed by the addition of increasing concentrations of Pc 
peptide. After washing, bound CK2D was determined by radioactivity counting. (C) Inhibition of 
CK2D/CK2E complex formation by different Pc peptide derivatives. Increasing concentrations of the 
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different peptides were tested as in (B). Pc (-Ÿ-), Linear peptide GAGGRLYGFKIHGGP (-Ŷ-), inverted 
linear peptide PGGHIKFGYLRGGAG (-'-), Head-to-tail peptide analogues: PcL1 RLYGFKIHPGAGG 
(-Ƒ-), PcL2 RLYGFKIHGPGAGG (-z-) and PcL3 RLYGFKIHGGPGAGG (-O-). Results are the means 
r S.D. (n = 3). 
Figure 8 Antagonist effects of peptide Pc variants carrying single-site mutations 
(A) Various Pc peptide variants generated by alanine scanning were tested at 1.5 PM (Ƒ) or 15 PM (Ŷ) for 
their antagonist effect on the association of CK2 subunits as described in figure 7C. The mean and 
standard deviation (n = 3) of representative experiment are shown. (B) IC50 values determined for each 
peptide variant.
Figure 9 Antagonist effect of Pc peptide on CK2-mediated phosphorylation of a CK2E-dependent
substrate
Preformed CK2 complexes were incubated for 15 min at 4°C with increasing concentrations of Pc peptide 
followed by the addition of GST-Olig2 (5 Pg) and 25 PM [J32P]-ATP-MgCl2 for 5 min at RT. 
Phosphorylated proteins were separated on SDS-PAGE and analyzed by autoradiography (upper panel) or 
Coomassie staining (lower panel). The results are representative of two independent experiments. C: 
control without CK2. 
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